Oncotype DX prostate cancer assay: Additional data

Genomic Health and researchers at the University of California, San Francisco, reported additional data from a clinical validation study in 395 patients with early stage prostate cancer showing that the Oncotype DX Genomic Prostate Score (GPS) significantly increased the number of patients identified as having very low risk disease and thus were appropriate for active surveillance to 26% from 5-10% using clinical measures alone. Specifically, >33% of patients originally classified as low risk based on clinical measures alone were identified by GPS as very low risk. Additionally, about 10% of patients originally classified as very low or low risk by clinical measures were identified by GPS as having more aggressive disease that would be considered for immediate treatment. Data were presented at the American Urological Association meeting in San Diego. Last September, Genomic Health and the UCSF researchers reported top-line data showing that the GPS met the primary endpoint by prospectively predicting adverse pathology from prostate needle biopsy tumor tissue samples (see BioCentury, Sept. 24, 2012). ...